Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
  • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
  • Contact Us
  • Menu Menu
You are here: Home1 / Media Centre2 / Press Releases3 / White Papers

White Papers

In these White Papers we describe the challenges of developing effective vaccines for Zika, Influenza (flu), and COVID-19 and explain the benefits of CD8+ priming, Emergex’s set-point vaccines and why we believe our approach addresses many of the issues:

  • COVID-19 White Paper – Update December 2020
  • The Case for T-Cell Vaccines for Elimination, and for Control of Transmission, of COVID-19 – 31 August 2020
  • CD8+ Priming as an Artificial Method for Inducing Herd Immunity into a Population White Paper – 3 April 2020
  • Scientific Rationale for the Use of T cell Priming to Limit the Spread of COVID-19 During Active Pandemic White Paper – 31 March 2020
  • A Case for a Universal Coronavirus Vaccine White Paper – 18 March 2020
  • Flu Vaccine White Paper – August 2018
  • Zika White Paper – August 2018

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top